SPY308.08+2.53 0.83%
DIA257.85+2.58 1.01%
IXIC9,608.38+56.33 0.59%

Morgan Stanley Maintains Overweight on Horizon Therapeutics, Raises Price Target to $50

Morgan Stanley maintains Horizon Therapeutics (NASDAQ:HZNP) with a Overweight and raises the price target from $39 to $50.

Benzinga · 05/08/2020 11:30

Morgan Stanley maintains Horizon Therapeutics (NASDAQ:HZNP) with a Overweight and raises the price target from $39 to $50.